



Substance Use Disorders

ATLAS on substance use (2010)

Resources for the prevention and treatment
of substance use disorders

ATLAS on substance use (2010)

Resources for the prevention and treatment
of substance use disorders

WHO Library Cataloguing-in-Publication Data

Atlas on substance use (2010): resources for the prevention and treatment of substance use disorders

1.Substance-related disorders - epidemiology. 2.Substance-related disorders - drug therapy. 3.Substance-related disorders - prevention and control. 4.Substance abuse. 5.Substance-related disorders - rehabilitation. 6.Health policy. 7.Health personnel. I.World Health Organization.

ISBN 978 92 4 150061 6

(NLM classification: WM 270)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: L'IV Com Sàrl, Le Mont-sur-Lausanne, Switzerland.

Printed in France.

FOREWORD

The global burden of disease attributable to alcohol and illicit drug use is significant by any measure; it amounts to 5.4% of the total burden of disease, according to the latest WHO estimates (WHO, 2009a). Another 3.7% of the global burden of disease is attributable to tobacco use. And disorders due to psychoactive substance use – including alcohol, drug and tobacco dependence – are the main underlying conditions ultimately responsible for the largest proportion of the global burden of disease attributable to substance use.

Effective strategies and interventions exist to prevent and treat substance use disorders. However, effective implementation of such strategies and interventions relies on several health system levels, including policy frameworks, the organization of prevention and treatment systems, and provision of prevention and treatment interventions in health care and other settings.

WHO's key functions include monitoring health situations and assessing trends. In recent years the WHO Department of Mental Health and Substance Abuse has produced a series of ATLAS reports on global resources for mental health and neurological conditions. The WHO project ATLAS-SU used a similar methodology to collect, compile and disseminate information from countries on resources that are available for the prevention and treatment of substance use disorders. This report has been developed on the basis of that information and provides a general overview of the availability and organization of prevention and treatment services for substance use disorders around the world, with particular focus on low- and middle-income countries.

The data presented in this report indicate that mental health services are the main providers of treatment for substance use disorders in less-resourced countries. In high-income countries, specialized services play a significant role in service provision for substance use disorders through a broad range of providers. Specialized services are important for consolidating and developing expertise and human resources, but improving the health and well-being of persons with substance use disorders – and their families – requires easily accessible and affordable services for those in need. Besides, in many less-resourced countries, specialization for health professionals in substance use disorders or addiction medicine is not available, or is available on only a very limited scale. In view of this situation, the most feasible way to improve coverage of treatment is to integrate prevention and treatment services for substance use disorders into health and social welfare systems, to make them available and implement them routinely in primary health care and other non-specialized settings as well as in the criminal justice system, and to ensure an appropriate provision of treatment or referral to treatment at different points of entry into the health and social care systems.

Recent initiatives and programmes of WHO, such as the mhGAP programme (WHO, 2008) and the development of the *mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings* (WHO, 2010), or the Joint UNODC-WHO programme on drug dependence treatment and care (UNODC/WHO, 2009),

are expected to improve the coverage and quality of prevention and treatment interventions for substance use disorders in low- and middle-income countries. They are also expected to contribute to bridging the gap between population needs and available services, particularly in health care systems.

Improving the coverage and quality of prevention and treatment interventions for substance use disorders requires well-developed and well-governed health care systems, properly educated and trained human resources, financial resources that are commensurate with population needs, supportive policy and legislative frameworks, and the availability of appropriate essential medicines. This publication is WHO's first attempt to cover all these areas at global level with information collected from 147 countries from around the world, representing 88% of the world population.

The data presented in this report are based on results of the questionnaire survey of focal points identified in WHO Member States, and on the efforts of WHO staff to ensure validity of data. There are many challenges in collecting and presenting this type of information, from the boundaries of prevention and treatment systems in different countries to ensuring a common understanding of the terms and concepts used in the data collection tools. It is acknowledged that these challenges result in limitations to the presented data. However, the focus of the report is on presenting an overall picture of available resources for treatment and prevention of substance use disorders globally, in WHO regions, and in groups of countries with different levels of economic development. In each subsequent round of data collection, all efforts will be made to improve the validity and comparability of the data so that trends can be monitored in the development of prevention and treatment resources for substance use disorders around the world. We hope that this report will be useful to a wide range of stakeholders, particularly those engaged in international efforts to improve the prevention and treatment of substance use disorders in low- and middle-income countries.

Dr Shekhar Saxena
Director
Department of Mental Health and Substance Abuse

Dr Vladimir Poznyak
Coordinator
Management of Substance Abuse
Department of Mental Health and Substance Abuse

CONTENTS

Foreword	iii
Acknowledgements	vii
Executive summary	ix
Introduction	1
Methodology	4
Chapter 1. Psychoactive substance use: epidemiology and burden of disease	7
1.1 Alcohol	7
1.2 Illicit drugs	9
1.3 Epidemiology of psychoactive substance use and burden of disease	11
1.4 Main psychoactive substances used in the treatment population	16
1.5 Substance use monitoring and surveillance	20
Chapter 2. Health services	23
2.1 Treatment of substance use disorders within health services	23
2.2 Government administration and budget of treatment services for substance use disorders	26
2.3 Financing treatment services for substance use disorders	29
2.4 Treatment settings for alcohol and drug use disorders	37
2.5 Treatment services and coverage of alcohol and drug use disorder treatment	43
2.6 Number of beds and length of stay	49
2.7 Care for special populations	52
Chapter 3. Pharmacological treatment	57
3.1 Pharmacological treatment of alcohol and drug use disorders	57
3.2 Policy framework and guidelines for the pharmacological treatment of substance use disorders	60
3.3 Availability of therapeutic drugs for alcohol and drug use disorders	63
3.4 Administration of opioid agonist pharmacotherapy	67
3.5 Supervision and prescription requirements for opioid agonist pharmacotherapy	70
Chapter 4. Human resources	75
4.1 The health workforce	75
4.2 Health professionals	78
4.3 Standards of care and supervision for health professionals	84
4.4 Nongovernmental organizations and self-help groups for substance use disorders	87

Chapter 5. Policy and legislation	93
5.1 Alcohol and drug treatment policy in public health perspective	93
5.2 Policy frameworks and special legislative provisions	96
5.3 The criminal justice system and substance use disorders	101
Chapter 6. Prevention	105
6.1 Effective prevention of substance use disorders	105
6.2 Administration and budget	109
6.3 Availability and coverage of prevention services	112
6.4 Prevention services in special populations and harm reduction	116
6.5 Screening and brief intervention programmes	120
6.6 Groups and agencies involved in prevention of substance use disorders	122
References	125
List of nominated focal points	132
List of countries according to WHO region	135
List of countries according to the World Bank list of economies	137

ACKNOWLEDGEMENTS

This report would not have been possible without the assistance of nominated focal points in World Health Organization (WHO) Member States who provided data and shared their knowledge and experience on the current situation regarding country resources for the prevention and treatment of substance use disorders. The contribution of the focal points is gratefully acknowledged. The list of nominated focal points in countries responding to the ATLAS survey is provided at the end of this report.

This report was produced in the framework of ATLAS-SU project implemented by the Management of Substance Abuse team of the Department of Mental Health and Substance Abuse of WHO headquarters in collaboration with WHO regional offices. The ATLAS-SU project builds on the mental health ATLAS project and aims to further the development of the global information system on resources for prevention and treatment of substance use disorders.

The ATLAS-SU project is implemented under the overall direction of Vladimir Poznyak. Shekhar Saxena and Benedetto Saraceno provided vision and guidance to the project. The principal writing of this report was done by Daniela Fuhr and Nicolas Clark. Other main contributors included Vladimir Poznyak and Alexandra Fleischmann. Data collation, compilation and statistical data analyses were carried out by Daniela Fuhr.

The data collection from countries and the production of this report would not have been possible without the collaboration of the WHO regional offices and the support of WHO's country offices. Key collaborators from WHO's regional offices, who also provided valuable contributions at different stages of the development of the report, include the following:

WHO African Region: Carina Ferreira-Borges, Therèse Agoussou and Albertine Koundi

WHO Region of the Americas: Maristela Monteiro and Linda Castagnola

WHO Eastern Mediterranean Region: Khalid Saeed

WHO European Region: Lars Møller and Anne-Majlis Jepsen

WHO South-East Asia Region: Vijay Chandra

WHO Western Pacific Region: Xiangdong Wang and Nina Rehn-Mendoza.

A number of colleagues at WHO headquarters gave advice during the course of the project, including Tarun Dua, Natalie Drew, Edwige Faydi, Michelle Funk, Jodi Morris, Mark van Ommeren, Dag Rekve, Isidora Vromans and Taghi Yasami.

A number of leading experts in the field of psychoactive substance use contributed to this report by providing expert texts for the respective chapters. They include:

Jürgen Rehm and Jayadeep Patra, Centre for Addiction and Mental Health (CAHM), Canada; Louisa Degenhardt, Murdoch Children's Research Institute, Burnet Institute, Australia; Thomas F. Babor, Department of Community Medicine, University of Connecticut School of Medicine, Farmington, CT, USA; Kerstin Stenius, Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; Robert Ali, WHO Collaborating Centre for the Treatment of Drug and Alcohol Problems, School of Medical Sciences, University

of Adelaide, Australia; Maria Elena Medina-Mora, National Institute on Psychiatry Ramon de la Fuente, Mexico; Robin Room, AER Centre for Alcohol Policy Research, Turning Point Alcohol & Drug Centre, Fitzroy, Victoria, Australia; School of Population Health, University of Melbourne, Australia; Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; and Tim Stockwell, Centre for Addictions Research of British Columbia; Department of Psychology, University of Victoria, BC, Canada.

During the development of this report, a number of people contributed in different capacities. Daniele Zullino and Delphine Sreekumar, Department of Psychiatry, Geneva University, Switzerland, provided their assistance with data entry. Mario Maj from the World Psychiatric Association and Tarek Gawad from the International Society of Addiction Medicine assisted with identifying the relevant data sources from some countries through their member associations.

David Bramley edited the report, and Irene Lengui developed graphic design and layout of the report. Emily Baron assisted with the production of graphs.

Teresita Narciso and Mylène Schreiber provided valuable administrative support in the preparation of the report.

Finally, WHO gratefully acknowledges the financial support of the Valencian Autonomous Government (Spain) for the development and publication of this report through the 2007–2010 Framework Collaborative Agreement between WHO and the Valencian Autonomous Government (Spain), the Health Authority, Valencian Health Agency.